Company Profiles

driven by the PitchBook Platform

Acetylon Pharmaceuticals

Description

Developer of small-molecule drugs. The company is developing next-generation selective small molecule histone deacetylase (HDAC) inhibitors, which allow for epigenetic regulation of gene and protein function for the treatment of patients with critical unmet medical needs.

2008

Founded

PRIVATE

Status

11-50

Employees

M&A

Latest Deal Type

$153M

Total Amount Raised

5

Investors

Description

Developer of small-molecule drugs. The company is developing next-generation selective small molecule histone deacetylase (HDAC) inhibitors, which allow for epigenetic regulation of gene and protein function for the treatment of patients with critical unmet medical needs.

Website:

www.acetylon.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals

Primary Office

Seaport Center, 70 Fargo Street Suite 205 Boston, MA 02210United States +1 (617) 245-1300
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Acetylon Pharmaceuticals's full profile, request a free trial.

Acetylon Pharmaceuticals Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Acetylon Pharmaceuticals Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Acetylon Pharmaceuticals Investors (5)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Individual InvestorAngel (individual)Minority000 0000000 0000
Leukemia & Lymphoma SocietyOtherMinority000 0000000 0000
Mondelez InternationalPE-Backed CompanyMinority000 0000000 0000
National Institutes of HealthGovernment000 0000000 0000
The Robert And Myra Kraft Family FoundationCorporate Venture CapitalMinority000 0000000 0000
Individual Investor Angel (individual)
Leukemia & Lymphoma Society Other
Mondelez International PE-Backed Company
National Institutes of Health Government
The Robert And Myra Kraft Family Foundation Corporate Venture Capital

Acetylon Pharmaceuticals Executive Team (14)

NameTitleBoard
Seat
Contact
Info
Walter OgierCo-Founder, Chief Executive Officer, President & Director
Min YangDirector, Biomarker Development
Faye SeyediDirector, Drug Substance Manufacturing
Ken JacobsDirector, Program Management
James Bradner MDCo-Founder & Board Member
Walter Ogier Co-Founder, Chief Executive Officer, President & Director
Min Yang Director, Biomarker Development
Faye Seyedi Director, Drug Substance Manufacturing
Ken Jacobs Director, Program Management
James Bradner MD Co-Founder & Board Member

Acetylon Pharmaceuticals Board Members (8)

NameRepresentingRoleSinceContact
Info
Bruce Downey JDSelfBoard Member000 0000
Elena Prokupets Ph.DSelfBoard Member000 0000
James Bradner MDAcetylon PharmaceuticalsCo-Founder & Board Member000 0000
Kenneth Anderson MDAcetylon PharmaceuticalsCo-Founder & Board Member000 0000
Marc CohenAcetylon PharmaceuticalsCo-Founder & Chairman000 0000
Bruce Downey JD Board Member Self
Elena Prokupets Ph.D Board Member Self
James Bradner MD Co-Founder & Board Member Acetylon Pharmaceuticals
Kenneth Anderson MD Co-Founder & Board Member Acetylon Pharmaceuticals
Marc Cohen Co-Founder & Chairman Acetylon Pharmaceuticals
Request full access to PitchBook